Analysts advised investors to subscribe to Concord Biotech IPO given its complex product portfolio, presence in niche space, strong client relationship and high entry barriers. The company is one of the leading global manufacturers of select fermentation-based APIs (F-APIs) across immunosuppressants and oncology with a market share of over 20% by volume in 2022.
F&O Talk| Nifty faces reversal signals and weaker breadth, key support at 24,500-24,400: Sudeep Shah of SBI Securities
The 50 component index Nifty 50 as well Sensex closed nearly 1.2% lower today. The former closed 293 points lower at 24,852 while the latter